Logo image of MRNA

MODERNA INC (MRNA) Stock Fundamental Analysis

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock

35.89  +1.83 (+5.37%)

After market: 36.75 +0.86 (+2.4%)

Fundamental Rating

3

Taking everything into account, MRNA scores 3 out of 10 in our fundamental rating. MRNA was compared to 572 industry peers in the Biotechnology industry. MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MRNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MRNA has reported negative net income.
In the past year MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
In multiple years MRNA reported negative operating cash flow during the last 5 years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B

1.2 Ratios

With an excellent Return On Assets value of -14.07%, MRNA belongs to the best of the industry, outperforming 84.60% of the companies in the same industry.
MRNA has a Return On Equity of -18.65%. This is amongst the best in the industry. MRNA outperforms 86.73% of its industry peers.
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROIC N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 80

1.3 Margins

The Gross Margin of MRNA (78.43%) is better than 86.19% of its industry peers.
MRNA's Gross Margin has declined in the last couple of years.
MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNA has less shares outstanding
MRNA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MRNA has an improved debt to assets ratio.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.46 indicates that MRNA is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.46, MRNA is doing good in the industry, outperforming 77.52% of the companies in the same industry.
MRNA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
MRNA has a worse Debt to Equity ratio (0.05) than 63.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 3.46
ROIC/WACCN/A
WACC11.04%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

MRNA has a Current Ratio of 4.39. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Current ratio (4.39) which is in line with its industry peers.
MRNA has a Quick Ratio of 4.20. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.20, MRNA is in line with its industry, outperforming 49.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.2
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

More info and screens

3

3. Growth

3.1 Past

MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.75%, which is quite impressive.
MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.29%.
Measured over the past years, MRNA shows a very strong growth in Revenue. The Revenue has been growing by 119.30% on average per year.
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%

3.2 Future

Based on estimates for the next years, MRNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.78% on average per year.
Based on estimates for the next years, MRNA will show a decrease in Revenue. The Revenue will decrease by -0.45% on average per year.
EPS Next Y23.67%
EPS Next 2Y12.3%
EPS Next 3Y13.01%
EPS Next 5Y13.78%
Revenue Next Year-49.27%
Revenue Next 2Y-32.3%
Revenue Next 3Y-16.81%
Revenue Next 5Y-0.45%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as MRNA's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.3%
EPS Next 3Y13.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

NASDAQ:MRNA (1/21/2025, 7:20:08 PM)

After market: 36.75 +0.86 (+2.4%)

35.89

+1.83 (+5.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-14 2025-02-14/amc
Inst Owners72.76%
Inst Owner Change-0.11%
Ins Owners5.46%
Ins Owner Change-0.04%
Market Cap13.81B
Analysts66.67
Price Target75.16 (109.42%)
Short Float %10.87%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.53%
Min EPS beat(2)3.51%
Max EPS beat(2)101.54%
EPS beat(4)4
Avg EPS beat(4)69.14%
Min EPS beat(4)3.51%
Max EPS beat(4)155.49%
EPS beat(8)6
Avg EPS beat(8)-1.23%
EPS beat(12)9
Avg EPS beat(12)4.31%
EPS beat(16)11
Avg EPS beat(16)-2.34%
Revenue beat(2)2
Avg Revenue beat(2)62.39%
Min Revenue beat(2)46.04%
Max Revenue beat(2)78.74%
Revenue beat(4)4
Avg Revenue beat(4)50.79%
Min Revenue beat(4)10.45%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)36.35%
Revenue beat(12)10
Avg Revenue beat(12)27.64%
Revenue beat(16)12
Avg Revenue beat(16)25.32%
PT rev (1m)-3.63%
PT rev (3m)-27.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-876.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-54.03%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)1.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.72
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-5.82
EYN/A
EPS(NY)-9.17
Fwd EYN/A
FCF(TTM)-10.28
FCFYN/A
OCF(TTM)-8.33
OCFYN/A
SpS13.2
BVpS30.99
TBVpS30.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.07%
ROE -18.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.43%
FCFM N/A
ROA(3y)18.74%
ROA(5y)2.74%
ROE(3y)31.99%
ROE(5y)4.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.72%
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.28%
Cap/Sales 14.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.2
Altman-Z 3.46
F-Score3
WACC11.04%
ROIC/WACCN/A
Cap/Depr(3y)117.07%
Cap/Depr(5y)134.11%
Cap/Sales(3y)4.65%
Cap/Sales(5y)15.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.31%
EPS Next Y23.67%
EPS Next 2Y12.3%
EPS Next 3Y13.01%
EPS Next 5Y13.78%
Revenue 1Y (TTM)-44.29%
Revenue growth 3Y104.31%
Revenue growth 5Y119.3%
Sales Q2Q%1.69%
Revenue Next Year-49.27%
Revenue Next 2Y-32.3%
Revenue Next 3Y-16.81%
Revenue Next 5Y-0.45%
EBIT growth 1Y19.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.26%
EBIT Next 3Y13.59%
EBIT Next 5Y16.78%
FCF growth 1Y-163.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-148.38%
OCF growth 3YN/A
OCF growth 5YN/A